Insider · CIK 0001456849

Dhingra Kapil

Reports to the SEC for 6 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001456849

Forms 4 and 5

Insider transactions

46 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-26	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2026-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+44.5K sh	—	—	44,500
2025-12-09	REPLReplimune Group, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,169 sh	—	—	0
2025-12-09	REPLReplimune Group, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,169 sh	$1.75	+$5,545.75	3,169
2025-12-09	REPLReplimune Group, Inc.S Sale	Director	SSale	−3,169 sh	$10.40	−$33K	0
2025-11-13	LAVA Therapeutics NVD Disposition to Issuer	Director	DDisposition to Issuer	−30K sh	—	—	0
2025-11-13	LAVA Therapeutics NVShare Options (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−33.4K sh	—	—	0
2025-08-19	CARGO Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2025-06-18	CARGO Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2025-06-12	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30.6K sh	—	—	30,550
2025-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+32K sh	—	—	32,000
2025-02-13	LAVA Therapeutics NVCommon Shares (Right to Buy)A Award	Director	AAward	+33.4K sh	—	—	33,390
2024-06-06	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30.6K sh	—	—	30,550
2024-06-04	CARGO Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+11.9K sh	—	—	11,871
2024-04-15	CARGO Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+49.3K sh	—	—	49,265
2024-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+32K sh	—	—	32,000
2023-05-16	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16.5K sh	—	—	16,500
2023-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25.2K sh	—	—	25,200
2022-06-10	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2022-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+16.5K sh	—	—	16,500
2021-06-18	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2021-04-16	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2021-04-16	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2021-04-16	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2021-04-16	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2021-04-16	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2021-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+16.5K sh	—	—	16,500
2021-01-19	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+29.8K sh	—	—	29,842
2020-12-07	REPLReplimune Group, Inc.S Sale	Director	SSale	−24.7K sh	$45.09	−$1.11M	15,325
2020-12-07	REPLReplimune Group, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+40K sh	$1.75	+$70K	40,000
2020-12-07	REPLReplimune Group, Inc. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−40K sh	—	—	3,169
2020-12-07	REPLReplimune Group, Inc.S Sale	Director	SSale	−1,802 sh	$47.04	−$84.8K	0
2020-12-07	REPLReplimune Group, Inc.S Sale	Director	SSale	−13.5K sh	$46.22	−$625K	1,802
2020-05-14	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2020-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+16.5K sh	—	—	16,500
2019-06-10	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2019-04-01	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+13.5K sh	—	—	13,500
2018-07-24	REPLReplimune Group, Inc. · Stock Option (right to buy)A Award	Director	AAward	+13.5K sh	—	—	13,500
2018-05-10	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2017-05-10	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2016-05-19	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	0
2015-12-02	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2011-06-23	MICROMET, INC.Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2010-06-22	MICROMET, INC.Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2009-06-17	MICROMET, INC.Stock Options (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2009-02-18	MICROMET, INC.Stock Option (Right to Buy)A Award	Director	AAward	+35K sh	—	—	35,000

Recent filings

Accepted (ET)
Jun 294
Dhingra Kapil0001456849-26-000002
SEC(opens sec.gov)
Apr 74
Dhingra Kapil0001104659-26-040570
SEC(opens sec.gov)
Dec 114
Dhingra Kapil0001104659-25-120332
SEC(opens sec.gov)
Nov 174
Dhingra Kapil0001456849-25-000005
SEC(opens sec.gov)
Aug 194
Dhingra Kapil0001610717-25-000306
SEC(opens sec.gov)
Jun 204
Dhingra Kapil0001610717-25-000246
SEC(opens sec.gov)
Jun 124
Dhingra Kapil0001415889-25-017050
SEC(opens sec.gov)
Apr 34
Dhingra Kapil0001104659-25-031831
SEC(opens sec.gov)
Feb 184
Dhingra Kapil0001415889-25-004527
SEC(opens sec.gov)
Jun 64
Dhingra Kapil0001610717-24-000303
SEC(opens sec.gov)
Jun 64
Dhingra Kapil0001415889-24-015819
SEC(opens sec.gov)
Apr 174
Dhingra Kapil0001610717-24-000209
SEC(opens sec.gov)
Apr 34
Dhingra Kapil0001104659-24-043255
SEC(opens sec.gov)
May 174
Dhingra Kapil0001415889-23-008241
SEC(opens sec.gov)
Apr 44
Dhingra Kapil0001104659-23-041733
SEC(opens sec.gov)
Jun 134
Dhingra Kapil0001415889-22-006517
SEC(opens sec.gov)
Apr 54
Dhingra Kapil0001104659-22-042758
SEC(opens sec.gov)

Companies

Address

C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 14TH FLOOR

CAMBRIDGE, MA, 02142